Eli Lilly (LLY) director acquires 6.129 stock units at $808.96
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025. The filing shows an acquisition of 6.129 shares of common stock at $808.96 per share, bringing the director’s direct beneficial ownership to 2,728.14 shares.
According to the footnote, the acquired amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 6.129 | $808.96 | $5K |
Footnotes (1)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Eli Lilly (LLY) disclose in this Form 4?
What is the nature of the acquired securities for LLY?
What is the post-transaction holding for the LLY director?
What was the transaction price reported for LLY?
What is the role of the reporting person at Eli Lilly (LLY)?
When did the LLY transaction occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.